IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Aktis Oncology Upsizes IPO Targeting $945.4 Million Valuation

Aktis Oncology, a Boston-based cancer drug developer, announced an upsized IPO aiming to raise $317.7 million. The company plans to sell 17.65 million shares at $16-$18 each, marking the first U.S. IPO of 2026. Eli Lilly has committed to a $100 million share purchase.

Insights:
Aktis Oncology, a Boston-based cancer drug developer, has announced an upsized initial public offering (IPO) targeting a valuation of up to $945.4 million. The company aims to raise as much as $317.7 million through the sale of 17.65 million shares, priced between $16 and $18 per share. The offering marks the first U.S. IPO of 2026, highlighting a strong start to the year for the biotech sector.
The Wall Street sign is displayed outside the New York Stock Exchange (NYSE) building on Tuesday after a widespread sell-off occurred on Monday in New York City, U.S., March 11, 2025. REUTERS/Shannon Stapleton
The Wall Street sign is displayed outside the New York Stock Exchange (NYSE) building on Tuesday after a widespread sell-off occurred on Monday in New York City, U.S., March 11, 2025. REUTERS/Shannon Stapleton
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.